

By Speed Post

F. No. 19(78)/2013/NPPA/Div II
National Pharmaceutical Pricing Authority
Department of Pharmaceuticals
Ministry of Chemicals & Fertilizers
Government of India

5th / 3rd Floor
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi – 110001
Dated 23.12.2014

OFFICE MEMORANDUM

Subject: Implementation of the review order of the Department of Pharmaceuticals.

In compliance to the review of DOP, NPPA has been directed to re-validate the data under para 9 of the DPCO, 2013 through a broad based survey. The working sheet of the notification is already available on the website of NPPA. In respect of the price order indicated below, all the concerned manufactures are requested to furnish further additional data / information if any, alongwith the supporting documents specifying the PTR and MAT value as on July, 2013 with in 15 days from the issue of this OM for this re-validation exercise being taken up by NPPA.

S.O. notification no. & Date
2101(E) dated 20.08.2014

Name of the formulaitons
Metformin HCL 500mg (SR) + Gliclazide
60mg (SR) + Pioglitazone HCL 7.5mg
tablet

(Signature)
(A.K. Khurana)
Director (Pricing)

Copy to:

1. Shri Anil Jain, Under Secretary, Department of Pharmaceuticals for information please w.r.t. the review order no. 31015/50/2014-PI.I dated 09.12.2014.
2. Apex Pharma organizations i.e. OPPI, IDMA, AISSPMA, FICCI, CII, IPA and FOPE for necessary action please.